drugset / Trial / NCT06544720
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Timeline
- Start
- 2023-08-02
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCG142 | Cell therapy | — | — |